{"id":"W4252327710","doi":"10.1097/00054725-200812003-00101","title":"Efficacy and Safety of Certolizumab Pegol in patients with active Crohnʼs Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study","year":2008,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Certolizumab pegol; Medicine; Infliximab; Clinical endpoint; Internal medicine; Maintenance therapy; Crohn's disease; Adalimumab; Interquartile range; Bristol-Myers; Open label; Adverse effect; Surgery; Gastroenterology; Clinical trial; Tumor necrosis factor alpha; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00264348,0.0006774731,0.00263212,0.0003194697,0.0003351842,0.0008366207,0.0004340242,0.001272397,0.001739963],"category_scores_gemma":[0.002127021,0.0003666046,0.001856166,0.0003192633,0.0007876367,0.001180105,0.000490061,0.001908059,0.0003448129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005328257,"about_ca_system_score_gemma":0.0005380556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004094808,"about_ca_topic_score_gemma":0.0008162895,"domain_scores_codex":[0.9992963,0.0003843985,0.00004156349,0.00009310662,0.00007711173,0.0001075276],"domain_scores_gemma":[0.9968195,0.001112773,0.0007446991,0.000245413,0.0001825568,0.000895036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9243961,0.009415572,0.02254271,0.0003807612,0.0007606198,0.0002564186,0.0002187357,0.0004256098,0.007103621,0.00004889059,0.0006483476,0.0338026],"study_design_scores_gemma":[0.4919604,0.40274,0.09772252,0.00009913298,0.001010488,0.000627118,0.0001340134,0.001381203,0.002219522,0.0001207054,0.001906642,0.0000782365],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977907,0.001240606,0.0001096352,0.0001207982,0.00004898375,0.000133417,0.0002538401,0.0000110955,0.000290846],"genre_scores_gemma":[0.9973708,0.0005187144,0.0002468318,0.0002757684,0.0001644821,0.0001918219,0.0006546502,0.000007723708,0.0005692284],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00264348,"threshold_uncertainty_score":0.01398021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01431606276899998,"score_gpt":0.2583093138341293,"score_spread":0.2439932510651293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}